S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
3 Safe Earnings Plays for a Risk-Off Market
Micron to bring microchip plant to upstate New York
Why is Russia reopening dormant copper mines? (Ad)
WTO predicts trade growth to slow next year amid crises
Live Updates: Russia-Ukraine War
Why is Russia reopening dormant copper mines? (Ad)
Stocks rise in extended rally, clawing back more ground
Don't Give Up on These Q3 Losers
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
3 Safe Earnings Plays for a Risk-Off Market
Micron to bring microchip plant to upstate New York
Why is Russia reopening dormant copper mines? (Ad)
WTO predicts trade growth to slow next year amid crises
Live Updates: Russia-Ukraine War
Why is Russia reopening dormant copper mines? (Ad)
Stocks rise in extended rally, clawing back more ground
Don't Give Up on These Q3 Losers
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
3 Safe Earnings Plays for a Risk-Off Market
Micron to bring microchip plant to upstate New York
Why is Russia reopening dormant copper mines? (Ad)
WTO predicts trade growth to slow next year amid crises
Live Updates: Russia-Ukraine War
Why is Russia reopening dormant copper mines? (Ad)
Stocks rise in extended rally, clawing back more ground
Don't Give Up on These Q3 Losers
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
3 Safe Earnings Plays for a Risk-Off Market
Micron to bring microchip plant to upstate New York
Why is Russia reopening dormant copper mines? (Ad)
WTO predicts trade growth to slow next year amid crises
Live Updates: Russia-Ukraine War
Why is Russia reopening dormant copper mines? (Ad)
Stocks rise in extended rally, clawing back more ground
Don't Give Up on These Q3 Losers
NASDAQ:SYRS

Syros Pharmaceuticals - SYRS Stock Forecast, Price & News

$6.64
+0.70 (+11.78%)
(As of 10/4/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.16
$6.81
50-Day Range
$5.34
$10.10
52-Week Range
$5.25
$48.00
Volume
217,364 shs
Average Volume
543,437 shs
Market Capitalization
$41.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.33

Syros Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
991.9% Upside
$72.50 Price Target
Short Interest
Healthy
12.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
0.97mentions of Syros Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$16,771 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($9.51) to ($4.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.95 out of 5 stars

Medical Sector

34th out of 1,087 stocks

Pharmaceutical Preparations Industry

10th out of 546 stocks

SYRS stock logo

About Syros Pharmaceuticals (NASDAQ:SYRS) Stock

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SYRS Stock News Headlines

Syros Pharmaceuticals (NASDAQ:SYRS) Raised to Hold at StockNews.com
What 4 Analyst Ratings Have To Say About Syros Pharmaceuticals
Biotech M&A returns as Vertex, Innoviva make buys
Syros Pharmaceuticals Tops Q1 EPS by 7c
Syros Pharmaceuticals Q1 2022 Earnings Preview
See More Headlines
Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SYRS Company Calendar

Last Earnings
8/09/2022
Today
10/05/2022
Next Earnings (Estimated)
11/04/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYRS
Fax
N/A
Employees
124
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$72.50
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+853.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-86,560,000.00
Net Margins
-433.67%
Pretax Margin
-433.67%

Debt

Sales & Book Value

Annual Sales
$23.49 million
Book Value
$13.76 per share

Miscellaneous

Free Float
5,494,000
Market Cap
$41.83 million
Optionable
Optionable
Beta
1.64

Key Executives

  • Dr. Nancy A. Simonian M.D. (Age 61)
    Pres, CEO & Director
    Comp: $939.4k
  • Dr. Richard A. Young Ph.D. (Age 68)
    Scientific Founder, Member of Scientific Advisory Board & Director
    Comp: $50k
  • Mr. Jason Haas (Age 54)
    Chief Financial Officer
    Comp: $457.22k
  • Dr. David A. Roth M.D. (Age 59)
    Chief Medical Officer
    Comp: $668.12k
  • Dr. James E. Bradner M.D. (Age 50)
    Founder
  • Dr. Nathanael S. Gray Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Gerald E. Quirk Esq. (Age 54)
    J.D., Sr. Advisor
  • Dr. Eric R. Olson Ph.D. (Age 64)
    Chief Scientific Officer
  • Courtney Solberg
    Mang. of Corp. Communications and Investor Relations
  • Dr. Christian C. Fritz Ph.D.
    Head of Biology













SYRS Stock - Frequently Asked Questions

Should I buy or sell Syros Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings
or view top-rated stocks.

What is Syros Pharmaceuticals' stock price forecast for 2022?

3 equities research analysts have issued 1 year price objectives for Syros Pharmaceuticals' shares. Their SYRS share price forecasts range from $30.00 to $100.00. On average, they predict the company's stock price to reach $72.50 in the next twelve months. This suggests a possible upside of 991.9% from the stock's current price.
View analysts price targets for SYRS
or view top-rated stocks among Wall Street analysts.

How have SYRS shares performed in 2022?

Syros Pharmaceuticals' stock was trading at $32.60 on January 1st, 2022. Since then, SYRS stock has decreased by 79.6% and is now trading at $6.64.
View the best growth stocks for 2022 here
.

When is Syros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our SYRS earnings forecast
.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings results on Tuesday, August, 9th. The company reported ($5.40) EPS for the quarter, missing the consensus estimate of ($4.20) by $1.20. The company earned $6.28 million during the quarter, compared to the consensus estimate of $4.68 million. Syros Pharmaceuticals had a negative net margin of 433.67% and a negative trailing twelve-month return on equity of 157.22%.

When did Syros Pharmaceuticals' stock split?

Syros Pharmaceuticals shares reverse split on the morning of Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $6.64.

How much money does Syros Pharmaceuticals make?

Syros Pharmaceuticals (NASDAQ:SYRS) has a market capitalization of $41.83 million and generates $23.49 million in revenue each year. The company earns $-86,560,000.00 in net income (profit) each year or ($17.30) on an earnings per share basis.

How many employees does Syros Pharmaceuticals have?

The company employs 124 workers across the globe.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The official website for the company is www.syros.com. The company can be reached via phone at (617) 744-1340 or via email at hannahd@sternir.com.

This page (NASDAQ:SYRS) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.